Literature DB >> 22927211

Characterization of TLR4 agonist effects on alhydrogel® sedimentation: a novel application of laser scattering optical profiling.

Christopher B Fox1.   

Abstract

Aluminum salt formulations such as Alhydrogel® have been used for decades as effective and safe vaccine adjuvants. Aluminum salts have a high adsorptive capacity for vaccine antigens and other immunomodulatory molecules such as Toll-like receptor (TLR) agonists. However, the characterization of some Alhydrogel®-adsorbed TLR agonists is challenging, requiring destructive analysis, complex instrumentation, and/or desorption method development. In this report, we characterize the effects of an Alhydrogel®-adsorbed synthetic Toll-like receptor 4 (TLR4) agonist on aluminum salt sedimentation behavior using laser scattering optical profiling. This method facilitates the detection of the effects on aluminum salt sedimentation behavior of low amounts of adsorbed TLR4 agonist (<30 μM) with a minimum of sample preparation and analysis time by collecting light transmission simultaneously from the complete vertical profile of the sample.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22927211     DOI: 10.1002/jps.23307

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

2.  In vitro evaluation of TLR4 agonist activity: formulation effects.

Authors:  Ayesha Misquith; H W Millie Fung; Quinton M Dowling; Jeffrey A Guderian; Thomas S Vedvick; Christopher B Fox
Journal:  Colloids Surf B Biointerfaces       Date:  2013-09-19       Impact factor: 5.268

3.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

4.  Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity.

Authors:  H W Millie Fung; Traci J T Mikasa; Julie Vergara; Sandra J Sivananthan; Jeffrey A Guderian; Malcolm S Duthie; Thomas S Vedvick; Christopher B Fox
Journal:  J Nanobiotechnology       Date:  2013-12-21       Impact factor: 10.435

5.  A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.

Authors:  Christopher B Fox; Sandra J Sivananthan; Malcolm S Duthie; Julie Vergara; Jeffrey A Guderian; Elliot Moon; David Coblentz; Steven G Reed; Darrick Carter
Journal:  J Nanobiotechnology       Date:  2014-04-26       Impact factor: 10.435

6.  Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Authors:  Christopher B Fox; Mark T Orr; Neal Van Hoeven; Sarah C Parker; Traci J T Mikasa; Tony Phan; Elyse A Beebe; Ghislain I Nana; Sharvari W Joshi; Mark A Tomai; James Elvecrog; Timothy R Fouts; Steven G Reed
Journal:  J Control Release       Date:  2016-11-12       Impact factor: 9.776

Review 7.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

Authors:  Harm HogenEsch; Derek T O'Hagan; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-10-10       Impact factor: 7.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.